These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12164394)

  • 1. Advantages and limitations of (non-)myeloablative allogeneic stem cell transplantation.
    Huugen D; Schouten HC; Bos GM
    Neth J Med; 2002 May; 60(4):162-9. PubMed ID: 12164394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-myeloablative allogeneic stem cell transplantation in patients with solid tumours and patients with a haematological malignancy.
    Huugen D; Bos GM; Jansen M; Lalisang R; Jansen R; Wagstaff J; Schouten HC
    Neth J Med; 2002 May; 60(4):170-3. PubMed ID: 12164395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Non-myeloablative allogeneic stem cell transplantation].
    Dalgaard J; Fløisand Y; Stenersen M; Egeland T; Brinch L
    Tidsskr Nor Laegeforen; 2007 Mar; 127(6):721-4. PubMed ID: 17363982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
    Resnick IB; Shapira MY; Slavin S
    Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies.
    Sureda A; Schmitz N
    Ann Hematol; 2003 Jan; 82(1):1-13. PubMed ID: 12574957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases.
    Satwani P; Cooper N; Rao K; Veys P; Amrolia P
    Bone Marrow Transplant; 2008 Jan; 41(2):173-82. PubMed ID: 18037944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level.
    Ivanov V; Faucher C; Mohty M; Bilger K; Ladaique P; Sainty D; Arnoulet C; Chabannon C; Vey N; Camerlo J; Bouabdallah R; Maraninchi D; Bardou VJ; Blaise D
    Transfusion; 2004 Apr; 44(4):501-8. PubMed ID: 15043564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immune reconstitution after allogeneic stem cell transplantation using nonmyeloablative or reduced-intensity conditioning regimen].
    Nakai K
    Nihon Rinsho; 2003 Sep; 61(9):1542-8. PubMed ID: 14515721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of disseminated adenovirus infections using quantitative plasma PCR in adult allogeneic stem cell transplant recipients receiving reduced intensity or myeloablative conditioning.
    Kalpoe JS; van der Heiden PL; Barge RM; Houtzager S; Lankester AC; van Tol MJ; Kroes AC
    Eur J Haematol; 2007 Apr; 78(4):314-21. PubMed ID: 17331130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
    Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
    Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
    Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF
    Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-myeloablative conditioning for hemopoietic stem cell transplantation--does it work?
    Cheong SK; Eow GI; Leong CF
    Malays J Pathol; 2002 Jun; 24(1):1-8. PubMed ID: 16329549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning.
    Steiner M; Matthes-Martin S; Attarbaschi A; Minkov M; Grois N; Unger E; Holter W; Vormoor J; Wawer A; Ouachee M; Woessmann W; Gadner H
    Bone Marrow Transplant; 2005 Aug; 36(3):215-25. PubMed ID: 15937510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.